GAIN: Assessing a Length Artificial Intelligence Algorithm to Estimate Length of Children

Sponsor
Danone Asia Pacific Holdings Pte, Ltd. (Industry)
Overall Status
Completed
CT.gov ID
NCT05079776
Collaborator
KK Women's and Children's Hospital (Other)
200
1
7.4
27.2

Study Details

Study Description

Brief Summary

An exploratory study to explore the possibility of using computer vision algorithms to estimate a child's length using images taken by a healthcare professional or parents.

Condition or Disease Intervention/Treatment Phase
  • Other: Physical length measurement

Detailed Description

This is an exploratory, observational, pilot study that aims to evaluate the performance of a Length Artificial Intelligence (LAI) algorithm in a real world setting. Images will be collected by parents or healthcare professionals, together with physical length measurements. This data will be used to evaluate the accuracy of the algorithm and to explore potential improvements. Data on the acceptance and experience of the using the algorithm will be collected for improvements.

Study Design

Study Type:
Observational
Actual Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Assessing the Use of a Growth Artificial Intelligence Algorithm for Estimating the leNgth of Children in Real-world Setting
Actual Study Start Date :
Nov 8, 2021
Actual Primary Completion Date :
Mar 8, 2022
Actual Study Completion Date :
Jun 20, 2022

Arms and Interventions

Arm Intervention/Treatment
Children aged 0-18 months of age

Children aged 0-18 months of age with no structural abnormalities of the lower limbs or orthopedic conditions

Other: Physical length measurement
Physical length will be measured and images will be collected for AI to estimate the length

Outcome Measures

Primary Outcome Measures

  1. Accuracy of the length AI [2 days]

    Accuracy of the length AI in a clinic and in a home setting, derived from: The length AI prediction from images collected The physical length measurement of subjects

Secondary Outcome Measures

  1. Investigator's assessment on collection of images [2 days]

    Investigator's assessment on the ease of collecting the images [Very Easy, Easy, Normal, Difficult, Very Difficult]

  2. Parental acceptability of the length AI [2 days]

    Parental acceptability of length AI assessed via the study questionnaire [Very useful, useful, neutral, not useful, very not useful]

  3. Investigators' (or delegates) acceptability of length AI [2 days]

    Investigators' (or delegates) likelihood of using the length AI assessed via the study questionnaire [Very Likely, Likely, Neutral, Unlikely, Very Unlikely]

Eligibility Criteria

Criteria

Ages Eligible for Study:
0 Months to 18 Months
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Children aged 0 to 18 months old.

  2. Parent(s) should have access to the internet and a smartphone or tablet to complete study questionnaires, take images and upload images.

  3. Parent(s) should be able to comprehend the content of the study and to complete the study questionnaires in English.

  4. Written consent from parent.

Exclusion Criteria:
  1. Parent(s) incapable of completing the study questionnaires and uploading of the images using smart phone or tablet with internet.

  2. Children unable to undergo length measurement (e.g. children with structural abnormalities of the lower limbs or orthopedic conditions such as club foot, hip dysplasia, etc).

Contacts and Locations

Locations

Site City State Country Postal Code
1 KK Women's and Children's Hospital Singapore Singapore 229899

Sponsors and Collaborators

  • Danone Asia Pacific Holdings Pte, Ltd.
  • KK Women's and Children's Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Danone Asia Pacific Holdings Pte, Ltd.
ClinicalTrials.gov Identifier:
NCT05079776
Other Study ID Numbers:
  • SBB20R&31696
First Posted:
Oct 15, 2021
Last Update Posted:
Jul 27, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Danone Asia Pacific Holdings Pte, Ltd.
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 27, 2022